Skip to main content

01.12.2017 | Case Report | Ausgabe 1/2017 Open Access

Diagnostic Pathology 1/2017

Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma

Diagnostic Pathology > Ausgabe 1/2017
Terufumi Kubo, Shintaro Sugita, Ryuichi Wada, Noriaki Kikuchi, Masahiro Iwasaki, Yumika Ito, Taro Sugawara, Hiromi Fujita, Makoto Emori, Ryoichi Tanaka, Hiroshi Hirano, Tsuyoshi Saito, Tadashi Hasegawa
Estrogen receptor
Endometrial stromal sarcoma
Fluorescence in situ hybridization
Gastrointestinal stromal tumor
Progesterone receptor


Uterine sarcoma is a rare tumor for which diagnosis is often difficult. According to the 2014 WHO classification, uterine sarcoma consists of leiomyosarcoma, low- and high-grade endometrial stromal sarcoma (ESS), and undifferentiated sarcoma [1]. Uterine gastrointestinal stromal tumor (GIST), although not listed in the WHO classification, is reported in some studies [2]. As newly identified gene rearrangements or immunophenotypes in uterine sarcomas may establish novel disease entities, detailed pathological investigation in each case is becoming increasingly important for appropriate evaluation of the tumor.
We encountered an unusual case of mesenchymal tumor with epithelioid morphology. The tumor arose from the uterine cervix exhibiting relatively low-frequency mitosis, smooth muscle differentiation, and c-kit expression. Furthermore, YWHAE gene rearrangement was detected by fluorescence in situ hybridization (FISH) in the tumor. These findings were suggestive of epithelioid leiomyosarcoma, high-grade ESS, or uterine GIST as differential diagnosis.

Case Presentation

A 52-year-old multiparous Japanese woman was referred to our hospital with a complaint of a feeling of abdominal fullness. She had uterine leiomyoma that had been observed for 9 years, and a history of chronic thyroiditis. Aside from the earlier observed leiomyoma, a previously unnoticed soft mass at the uterine cervix was palpable on pelvic examination. T1-weighted magnetic resonance imaging with fat suppression revealed a swollen uterine corpus with leiomyoma, and suggested a uterine cervical lesion with a low signal intensity (Fig. 1). Circulating levels of CA 125 and CA 19–9 were within the reference range at 16.3 and 11 U/mL, respectively. Hysterectomy was performed with a clinical diagnosis of multiple leiomyomas and an unknown cervical tumor. Postoperatively, the patient underwent adjuvant chemotherapy (gemcitabine plus docetaxel) and did well for the next 3 months, with neither local recurrence nor distant metastasis on chest and abdominal computed tomography imaging.
The enlarged uterus was 8 × 14 × 8.5 cm in size. Several elastic, hard, whitish masses were found in the uterine corpus, consistent with leiomyoma. In addition, an elastic, soft gray-white hemorrhagic mass measuring 8 × 6 × 5 cm was observed at the anterior wall of the uterine cervix (Fig. 2a).
Histologically, the cervical mass was below the squamous epithelium and consisted of a nest-like proliferation of less cohesive, epithelioid tumor cells that had rounded nuclei and eosinophilic cytoplasm. The tumor cells had no marked nuclear pleomorphism and prominent nucleoli, and a coarse chromatin pattern was found in the nucleus. Mitotic figures were moderately frequent (4 per high-power field) but atypical mitoses were not present (Fig. 2c). The tumor showed a confluent growth pattern and individual nests of tumor cells were compartmentalized by intricate vasculature (Fig. 2b). There was no apparent involvement of myometrial smooth muscle cells. Foci of extensive necrosis and hemorrhage were found in some areas. A low-grade ESS component, showing uniform cells with round to spindle-shaped nuclei, which were whorled around arteriole-type vessels, was not coexistent in the lesion.
Immunohistochemically, the tumor cells were diffusely positive for vimentin (clone V9, DAKO, Glostrup, Denmark), α-smooth muscle actin (αSMA; clone 1A4, DAKO; Fig. 3a), muscle-specific actin (clone HHF-35, DAKO), and heavy caldesmon (clone h-CD, DAKO), with moderate positivity for c-kit (DAKO; Fig. 3b), estrogen receptor (ER; clone SP1, Ventana, Tucson, AZ; Fig. 3c), and progesterone receptor (PgR; clone 1E2, Ventana). In contrast, the cells were negative for pan-cytokeratin (clone AE1/AE3, DAKO), desmin (clone D33, DAKO), CD10 (clone 56C6, Novocastra, Newcastle upon Tyne, United Kingdom), CD34 (clone QBEnd10, DAKO), p16 (clone E6H4, Roche, Basel, Switzerland), DOG1 (clone K9, Leica Biosystems, Wetzlar, Germany) and cyclin D1 (Biocare, Concord, CA). The Ki-67 (clone 30–9, Roche) labeling index of the neoplastic cells was 19.5%. These histological and immunohistochemical findings suggested a differential diagnosis of non-epithelial tumor of the uterus, particularly high-grade ESS, epithelioid leiomyosarcoma, or uterine GIST.
FISH was performed for further molecular biological observations. To detect YWHAE rearrangement derived from chromosomal translocation of t(10;17)(q22;p13)—we used a custom dual-color, split-signal YWHAE probe set for the YWHAE locus on chromosome 17p13 (Chromosome Science Lab, Inc., Sapporo, Japan). The probe set consisted of a 333-kilobase (kb) sequence labeled with SpectrumGreen (telomeric [RP11-143 L7 and RP11-22G12]) and a 303-kb sequence labeled with SpectrumOrange (centromeric [RP11-100 F18 and RP11-60C18]). Rearrangements in the NUTM2A and NUTM2B genes at 10q23 and 10q22, respectively, were characterized using a custom break-apart probe design. The probes were synthesized using oligo-based SureFISH technology (Agilent Technologies, Santa Clara, CA) and labeled with FITC (5’ probe) and Cy3 (3′ probe) fluorophores. The analysis was performed with formalin-fixed, paraffin-embedded specimens sectioned into 3-μm-thick slices, as described previously [3]. The split-signal rate of YWHAE, NUTM2A and NUTM2B was 18%, (Fig. 3d), 0 and 4%, respectively, when 50 nuclei were counted. In contrast, a JAZF1 split, which is a major gene translocation in low-grade ESS, [4] was not detected.
To investigate KIT and PDGFRA gene mutations, direct sequence analysis was performed. Exons 9, 11, and 13 of the KIT gene and exon 18 of the PDGFRA gene were amplified by polymerase chain reaction using the primers KITexon9F: GGC TTT TGT TTT CTT CCC TTT A, KITexon9R: ATG GTA GAC AGA GCC TAA ACA, KITexon11F: GAT CTA TTT TTC CCT TTC TCC C, KITexon11R: AGC CCC TGT TTC ATA CTG AC, KITexon13F: GCT TGA CAT CAG TTT GCC AG, KITexon13R: GCA GCT TGG ACA CGG CTT T, PDGFRAexon18F: CAG ATG GCT TGA TCC TGA GT, and PDGFRAexon18R: GAG GAT GAG CCT GTC CAG T. The amplified products were purified and sequenced. The sequences of KIT exons 9, 11, and 13 were wild type. In PDGFRA exon 18, substitution of nucleotide C to T, known as a single-nucleotide variant (rs2228230) was detected in one allele. The variant does not cause amino acid substitution. Thus, it was considered that there was no oncogenic mutation in KIT and PDGFRA genes in this tumor.


This tumor consisted predominantly of round cells with a modest amount of eosinophilic to granular cytoplasm, irregular nuclear contour, and granular to vesicular chromatin with variably prominent nucleoli. Neoplastic cells were arranged in a nest-like structure compartmentalized by delicate vasculature. Although the current case conformed exactly to the morphological definition of high-grade ESS, the mitotic activity was inconspicuous. Immunohistochemically, c-kit and cyclin D1 are considered to be critical markers in diagnosing high-grade ESS [5, 6]. While the cell membrane and cytoplasm were positive for c-kit in the current case, there was no nuclear staining of cyclin D1. The diffuse positive signals for ER and PgR found in this case are also uncommon in high-grade ESS. The tumor cells were positive for some smooth muscle and myogenic markers including αSMA, muscle-specific actin, and heavy caldesmon, which have not been previously reported in high-grade ESS [7]. These immunophenotypes might indicate epithelioid leiomyosarcoma rather than high-grade ESS.
In addition to morphological and immunohistochemical findings, molecular biological investigations offer a sophisticated approach that provides critical information for accurately diagnosing some types of bone and soft tissue tumors. Lee et al. reported that high-grade ESS typically harbors a YWHAE-NUTM2 fusion gene [8]. The current case harbored 18% of YWHAE gene rearrangement. Conversely, the frequencies of NUTM2A and NUTM2B split signals were far lower than that of YWHAE. Although a small number of split signals is considered to be sufficient evidence of gene rearrangement in the diagnosis for some types of tumors, a relevant threshold of YWHAE split signals for diagnosing high-grade ESS under the current concept is reported to be 20% [9]. Furthermore, YWHAE gene rearrangement may not be a specific finding for high-grade ESS. It was reported that translocation of t(10;17), including the YWHAE gene, was detected in a uterine sarcoma that was diagnosed as a poorly differentiated uterine tumor with t(10;17) translocation and neuroectodermal phenotype [10]. The c-kit positivity seen in the current case might possibly be suggestive of a uterine GIST. However, the results of direct sequencing revealed that there was no mutation in exons 9, 11, and 13 of the KIT gene or in exon 18 of the PDGFRA gene in the tumor. Based on all these findings, the tumor was designated as uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement.


In conclusion, the tumor in this case seems quite instructive, showing a potential diagnostic pitfall of uterine sarcoma with epithelioid morphology. The tumor had some immunohistochemical features of leiomyosarcoma, high-grade ESS, and uterine GIST. In addition to the conventional practices for pathological diagnosis, molecular biological analysis led to a more definitive diagnosis. Interestingly, this uterine sarcoma exhibited unusual gene rearrangement for leiomyosarcoma. Accumulation of additional cases may enable an appropriate evaluation of prognosis, better treatment, and a novel paradigm for this disease.





Availability of data and materials

There are no additional supporting data available.

Authors’ contributions

TK and SS carried out histopathological evaluation and drafted the manuscript. RW performed direct sequencing. NK, YI, TS, HF, and HH assisted with the pathological analysis. RT, MI, ME, and TS collected the clinical and surgical data. TH conceived of the study and participated in the design, and the preparation of the manuscript. All authors read and approved the final manuscript.

Competing interests

There are no conflicts of interests in this study.

Consent for publication

The patient gave general consent for the use of their tissue/data for research purposes as authorized by the Institutional Review Board of Sapporo Medical University Hospital (282–65). Written informed consent for publication of clinical details and clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.

Ethics approval and consent to participate

The ethical approval and documentation for a case report was waived with approval of the Institutional Review Board of Sapporo Medical University Hospital.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Diagnostic Pathology 1/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

27.06.2019 | Nebennierentumoren | CME | Ausgabe 4/2019

Tumoren der Nebenniere

Aktualisierter Überblick

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Diagnostik und Management von Gefäßmalformationen

Interdisziplinäres Teamwork gefragt

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Systemische Therapie von Sarkomen

Neue Biomarker und Therapiestrategien

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Epitheloide, biphasische und Mischtumoren des Weichgewebes